First-in-human phase I trial of YS 110 in patients with advanced cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs YS 110 (Primary)
- Indications Liver cancer; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Ys Therapeutics
- 14 Mar 2017 Results published in the British Journal of Cancer
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from planning to completed, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.